Elan Prialt pricing
Executive Summary
Annualized price for Elan's non-opioid pain agent Prialt (ziconotide) for typical patient weighing 70 kg is $18,250, assuming dosing every six weeks. Elan describes Prialt rollout as a "quiet launch" focusing on 50 pain centers. FDA approved the product Dec. 28 and Elan launched the week of Jan. 24 (1"The Pink Sheet" Jan. 3, 2005, p. 4)...
You may also be interested in...
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.